Brief: United Therapeutics Corporation Announces Teton-2 Pivotal Study Of Tyvaso® Meets Primary Endpoint For The Treatment Of Idiopathic Pulmonary Fibrosis
02/09/2025 13:42
United Therapeutics Corp UTHR.O: UNITED THERAPEUTICS CORPORATION ANNOUNCES TETON-2 PIVOTAL STUDY OF TYVASO® MEETS PRIMARY ENDPOINT FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS UNITED THERAPEUTICS CORP: STUDY MEETS SEVERAL KEY SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE UNITED THERAPEUTICS CORP - TETON-2 STUDY MEETS PRIMARY ENDPOINT FOR IPF UNITED THERAPEUTICS : TREATMENT WITH TYVASO WAS WELL-TOLERATED, SAFETY PROFILE WAS CONSISTENT WITH PREVIOUS TYVASO STUDIES UNITED THERAPEUTICS CORP: TO USE DATA FROM TETON-2 STUDY AND ONGOING TETON-1 STUDY OF NEBULIZED TYVASO TO SUPPORT A SUPPLEMENTAL NDA UNITED THERAPEUTICS CORP - TO USE TETON DATA FOR TO SUPPORT SNDA TO ADD IPF TO LABELED INDICATIONS FOR NEBULIZED TYVASO Source text: ID:nBw49fWsCa Further company coverage: UTHR.O
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug